Literature DB >> 18713988

KLRE/I1 and KLRE/I2: a novel pair of heterodimeric receptors that inversely regulate NK cell cytotoxicity.

Per C Saether1, Ingunn H Westgaard, Sigurd E Hoelsbrekken, Jonathan Benjamin, Lewis L Lanier, Sigbjørn Fossum, Erik Dissen.   

Abstract

NK cells identify infected, neoplastic, or MHC-disparate target cells via several different receptors. The NK cell receptor KLRE1 lacks known signaling motifs but has nevertheless been shown to regulate NK cell-mediated cytotoxicity. Here we demonstrate that KLRE1 forms functional heterodimers with either KLRI1 or KLRI2. Cotransfection with KLRE1 was necessary for surface expression of the NK cell receptor chains KLRI1 and KLRI2 in 293T cells. Moreover, KLRE1 can be coimmunoprecipitated with KLRI1 or KLRI2 from transfected NK cell lines. By flow cytometry, KLRE1 and KLRI1 showed colinear expression on NK cells, suggesting surface expression as heterodimers. Unlike other killer cell lectin-like receptors, KLRE1/KLRI1 and KLRE1/KLRI2 heterodimers predominantly migrated as single chains in SDS-PAGE, indicating noncovalent association. KLRI1 was coimmunoprecipitated with the tyrosine phosphatase Src homology region 2 domain-containing phosphatase 1. In accordance with an inhibitory function, anti-HA Ab induced reduced killing of FcR-bearing targets by KLRI1-HA-transfected NK cell lines in a redirected cytotoxicity assay. Reciprocally, KLRI2-HA transfectants displayed increased killing in this assay. Finally, Ab to KLRE1 induced inhibition in KLRI1-transfected cells but increased cytotoxicity in KLRI2 transfectants, demonstrating that KLRE/I1 is a functional inhibitory heterodimer in NK cells, whereas KLRE/I2 is an activating heterodimeric receptor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713988      PMCID: PMC2577148          DOI: 10.4049/jimmunol.181.5.3177

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Expression of CD43 epitopes on NK and T cells.

Authors:  S Høysaeter; W Jensen; S Fossum
Journal:  Scand J Immunol       Date:  1994-10       Impact factor: 3.487

Review 2.  Positive and negative MHC class I recognition by rat NK cells.

Authors:  B Rolstad; J T Vaage; C Naper; D Lambracht; K Wonigeit; E Joly; G W Butcher
Journal:  Immunol Rev       Date:  1997-02       Impact factor: 12.988

3.  Biochemical and immunological properties of rat recombinant interleukin-2 and interleukin-4.

Authors:  A J McKnight; B J Classon
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

4.  Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits.

Authors:  S Lazetic; C Chang; J P Houchins; L L Lanier; J H Phillips
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

5.  Two subsets of rat T lymphocytes defined with monoclonal antibodies.

Authors:  R J Brideau; P B Carter; W R McMaster; D W Mason; A F Williams
Journal:  Eur J Immunol       Date:  1980-08       Impact factor: 5.532

6.  NKp46 defines a subset of bovine leukocytes with natural killer cell characteristics.

Authors:  Anne K Storset; Siri Kulberg; Ingvild Berg; Preben Boysen; Jayne C Hope; Erik Dissen
Journal:  Eur J Immunol       Date:  2004-03       Impact factor: 5.532

7.  Role of a NK receptor, KLRE-1, in bone marrow allograft rejection: analysis with KLRE-1-deficient mice.

Authors:  Eiko Shimizu; Junzo Koike; Hiroshi Wakao; Ken-Ichiro Seino; Haruhiko Koseki; Terutaka Kakiuchi; Toshinori Nakayama; Masaru Taniguchi
Journal:  Blood       Date:  2004-04-06       Impact factor: 22.113

8.  Allogeneic lymphocyte cytotoxicity (ALC) in rats: establishment of an in vitro assay, and direct evidence that cells with natural killer (NK) activity are involved in ALC.

Authors:  B Rolstad; S Fossum
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

9.  Bone marrow allograft rejection mediated by a novel murine NK receptor, NKG2I.

Authors:  Junzo Koike; Hiroshi Wakao; Yuko Ishizuka; Taka-aki Sato; Masaru Hamaoki; Ken-ichiro Seino; Haruhiko Koseki; Toshinori Nakayama; Masaru Taniguchi
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

10.  The lectin-like receptor KLRE1 inhibits natural killer cell cytotoxicity.

Authors:  Ingunn H Westgaard; Erik Dissen; Knut M Torgersen; Sasha Lazetic; Lewis L Lanier; Joseph H Phillips; Sigbjorn Fossum
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  5 in total

1.  Identification of natural killer cell receptor clusters in the platypus genome reveals an expansion of C-type lectin genes.

Authors:  Emily S W Wong; Claire E Sanderson; Janine E Deakin; Camilla M Whittington; Anthony T Papenfuss; Katherine Belov
Journal:  Immunogenetics       Date:  2009-07-14       Impact factor: 2.846

2.  Paired opposing leukocyte receptors recognizing rapidly evolving ligands are subject to homogenization of their ligand binding domains.

Authors:  Sigbjørn Fossum; Per Christian Saether; John Torgils Vaage; Michael Rory Daws; Erik Dissen
Journal:  Immunogenetics       Date:  2011-07-01       Impact factor: 2.846

3.  The evolution of the natural killer complex; a comparison between mammals using new high-quality genome assemblies and targeted annotation.

Authors:  John C Schwartz; Mark S Gibson; Dorothea Heimeier; Sergey Koren; Adam M Phillippy; Derek M Bickhart; Timothy P L Smith; Juan F Medrano; John A Hammond
Journal:  Immunogenetics       Date:  2017-02-09       Impact factor: 2.846

4.  Natural Killer Cell Receptor Genes in Camels: Another Mammalian Model.

Authors:  Jan Futas; Jan Oppelt; April Jelinek; Jean P Elbers; Jan Wijacki; Ales Knoll; Pamela A Burger; Petr Horin
Journal:  Front Genet       Date:  2019-07-02       Impact factor: 4.599

5.  Rat macrophage C-type lectin is an activating receptor expressed by phagocytic cells.

Authors:  Ana Lobato-Pascual; Per Christian Saether; Maria K Dahle; Peter Gaustad; Erik Dissen; Sigbjørn Fossum; Michael R Daws
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.